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Does Nitroglycerin
Therapy Hit the Endothelium?*
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Nitrates are still widely used in the management of coronary
artery disease (CAD) in patients with stable and unstable
angina, acute myocardial infarction and congestive heart
failure. The therapeutic efficacy of these nitrates is due to
peripheral venous and arterial dilation that results in de-
creased myocardial oxygen consumption. Nitrates also dilate
large coronary arteries and collaterals while having minimal
or no effect on arteriolar tone. It is assumed that nitroglyc-
erin (NTG) induces vasorelaxation by releasing the vasoac-
tive principle nitric oxide (NO) via an enzymatic biotrans-
formation step. Nitric oxide, an endothelium-derived
relaxing factor, activates the target enzyme soluble guanylyl
cyclase (sGC) and increases tissue levels of the second
messenger cyclic guanosine monophosphate (cGMP). Cy-
clic GMP in turn activates a cGMP-dependent protein
kinase which has been shown to mediate vasorelaxation via
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phosphorylation of proteins that regulate intracellular Ca21
levels. Nitric oxide released from NTG may also beneficially
influence the process of atherosclerosis by reducing neutro-
phil adhesion to the endothelium and by inhibiting the
expression of adhesion molecules and platelet aggregation.
Despite the beneficial hemodynamic profile and potential
antiatherogenic effects of NTG, the efficacy of this kind of
treatment in patients with CAD remains disappointing
(1,2). In fact, a recent meta-analysis even indicates that the
long-term use of nitrates may be deleterious for patients
with ischemic heart disease (3).
NITRATE TOLERANCE
AND CROSS-TOLERANCE
Although acute application of NTG exhibits high vasodi-
lator and anti-ischemic efficacy, this activity is rapidly lost
on long-term treatment due to the development of nitrate
tolerance (4). The mechanisms underlying this phenome-
non are likely to be multifactorial and may involve neuro-
hormonal counter-regulatory mechanisms, impaired NTG
biotransformation or changes intrinsic to the vasculature.
A phenomenon related to nitrate tolerance is cross-
tolerance to other endothelium-dependent and -independent
nitrovasodilators. This has been observed most commonly
in situations in which NTG was administered long term in
vivo in experimental animal models (4–6) and is not
encountered in situations in which nitrate tolerance is
induced by short-term exposure of vascular segments in
vitro (7). It remains to be established whether nitrate
therapy may adversely affect endothelial function in humans,
a question that needs to be addressed since endothelial
dysfunction has been shown to be a predictor of adverse
long-term outcome in patients with CAD (8).
In this issue of the Journal, Gori et al. (9) present a paper
that examines the effect of long-term NTG treatment on
endothelial function of the forearm circulation of healthy
volunteers. Endothelial function was assessed using strain
gauge plethysmography. The NTG dose was 0.6 mg/h/d,
which produces an average NTG concentration of about
0.1 mg/kg/min. The treatment period was 6 days and the
study was designed in an investigator-blind parallel fashion.
Flow responses of the brachial artery were studied in
response to intra-arterial infusion of the endothelium-
dependent vasodilator acetylcholine (ACh) and the NO
synthase inhibitor NG-monomethyl-L-arginine (L-
NMMA). Continuous treatment with NTG patches for 6
days resulted in a marked inhibition of ACh-induced
increases in forearm blood flow as compared to the control
group without NTG pretreatment. Likewise, L-NMMA
induced vasoconstriction was significantly blunted in volun-
teers treated with NTG. The lowest concentration of
L-NMMA was even able to cause a paradoxical dilation.
Based on the findings, the authors concluded that NTG
treatment has an inhibitory effect on basal as well as on
stimulated vascular NO-bioavailability and that this is, at
least in part, due to abnormalities in NO synthase (NOS
III) function.
Similar findings have previously been established in the
coronary circulation of patients treated continuously with
NTG for a 5-day period with NTG patches. Using ACh-
induced vasoconstriction as a surrogate parameter for endo-
thelial function in large coronary arteries, Caramori et al.
(10) found that continuous treatment with NTG leads to
enhanced ACh-induced vasoconstriction. The interpreta-
tion of the results of this study may be confounded by the
fact that long-term NTG treatment also causes a hypersen-
sitivity to vasoconstricting agonists (11) by activating the
second messenger protein kinase C (PKC) and by stimu-
lating the expression of endothelin-1 within the smooth
muscle layer (12). Thus, by studying ACh-induced vaso-
constriction in the coronary circulation, it may be difficult to
differentiate whether this phenomenon is due to endothelial
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dysfunction or secondary to NTG-induced hyper-reactivity
of the smooth muscle layer to constricting agonists, a
question that is now addressed by the results of the Gori et
al. (9) study.
MECHANISMS UNDERLYING NTG-INDUCED
DIMINISHED VASCULAR NO BIOAVAILABILITY
The attenuated ACh forearm blood flow response and the
attenuated L-NMMA response in healthy volunteers indi-
cate diminished vascular NO bioavailability in response to
long-term NTG treatment. As discussed by Gori et al. (9),
several reasons may account for this phenomenon such as a
decrease in the expression of NOS III, a dysfunctional NOS
III due to intracellular L-arginine or tetrahydrobiopterin
deficiency, increased vascular superoxide production or a
desensitization of the NO target enzyme sGC at the smooth
muscle level as suggested by Molina et al. (5). At first
glance, it seems difficult to see how these quite different
mechanisms may fit into one solid concept. A closer look,
however, indicates that all of these findings may be ex-
plained by an NTG-induced increase in vascular superoxide
production.
Evidence for a role of oxidative stress in tolerance and
cross-tolerance was first provided by experimental studies
showing that superoxide dismutase (SOD) was able to
improve tolerance as well as cross-tolerance to ACh (4).
Subsequently, in vitro as well as in vivo treatment with
NTG has been shown to be associated with increased
superoxide levels in endothelial as well as in smooth muscle
cells (13,14). The stimulation of vascular superoxide pro-
duction by NTG therapy may have several consequences.
First, increased superoxide production in endothelial and
smooth muscle cells may inhibit the vasodilator potency of
NTG simply by inactivating NO released from NTG
during the biotransformation process.
Second, superoxide combines with NO in a diffusion-
limited reaction that is about 10 times faster than the
dismutation of superoxide by SOD. This reaction produces
peroxynitrite, a compound with limited NO-like bioactivity
thereby “shunting” NO away from its typical target func-
tions such as vasodilation and platelet inhibition. In vitro as
well as in vivo data indicate that NTG treatment increases
vascular (15) and urinary nitrotyrosine levels (16), which can
be considered as a marker of peroxynitrite-dependent oxi-
dative damage. There is a growing body of evidence show-
ing that increased vascular peroxynitrite formation may also
have deleterious consequences for the function of the NOS
III. As pointed out by Gori et al. (9), peroxynitrite is a
strong stimulus for the oxidation of the NOS III cofactor
tetrahydrobiopterin (BH4) to dihydrobiopterin (BH2) (17).
The resulting intracellular BH4 deficiency may lead to an
uncoupling of NOS III (18). Thus, NTG therapy may
switch NOS III from a NO to a superoxide-producing
enzyme, which may further increase oxidative stress in
vascular tissue in a positive feedback fashion. Indeed, an
uncoupled NOS III has recently been demonstrated in an
animal model of nitrate tolerance since an inhibitor of NOS
III, L-NNA was able to significantly reduce vascular super-
oxide production in tolerant vessels (19). In addition,
supplementation of NTG-treated rats with BH4 was able to
reverse NTG-induced endothelial dysfunction (20). A sec-
ond mechanism of NOS III uncoupling may be intracellular
depletion of L-arginine (21). Incubation of cultured endo-
thelial cells or vascular tissue with NTG has been shown to
reduce the vasodilator potency of NTG, to deplete intracel-
lular L-arginine levels (22) and to stimulate endothelial cells
to produce superoxide (23). Since endothelial superoxide
production was blocked by NOS III inhibitors and tolerance
was improved by L-arginine, the authors concluded that
NTG-induced increases in superoxide production may be at
least in part secondary to NOS III uncoupling due to
L-arginine deficiency (23). It is not very likely that endo-
thelial dysfunction is secondary to decreased expression of
NOS III since recent experimental studies have shown that
in the setting of tolerance, the enzyme is upregulated rather
than downregulated (19).
Third, superoxide has recently been shown to be a potent
stimulus for the activation of PKC in endothelial cells (24).
In turn, PKC may phosphorylate NOS III, therefore
leading to an inhibition of activity and inhibition of NO
production by the enzyme (25).
Fourth, superoxide has also been shown to have a potent
inhibitory effect on the activity of the NO downstream
target, the sGC (26) and cGMP-dependent protein kinase
action (13,27), which may partly explain the trend for a
desensitization of the sodium nitroprusside dose response
relationship for blood flow responses as described by Gori et
al. (9).
The fact that NTG therapy indeed stimulates super-
oxide production in human tissue was recently shown by
Sage et al. (28) in patients undergoing bypass surgery.
However, the authors failed to demonstrate any cross-
tolerance to endothelium dependent and independent vaso-
dilators and in vitro modulation of vascular superoxide
production did not modify the NTG-dose response rela-
tionship. In addition, they established a decreased tissue
content of 1,2 glyceryl dinitrate in tolerant tissue, which
was used as an argument to conclude that impaired NTG-
biotransformation specifically accounts for tolerance and
that endothelial function is preserved (28). Although dif-
ferences in the vessel region studied (conductance vs.
resistance vessels) as well as differences in the duration of
NTG treatment (1 vs. 6 days) make it difficult to compare
these two studies, the recent demonstration of cross-
tolerance to endothelium-dependent vasodilators in coro-
nary arteries (10) and the results of the present study (9)
challenge the concept that impaired NTG biotransforma-
tion is the sole reason for nitrate tolerance.
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STRATEGIES TO PREVENT THE DEVELOPMENT
OF TOLERANCE AND CROSS-TOLERANCE
Which strategy is the best to prevent the development of
tolerance and cross-tolerance? The most widely accepted
approach to prevent the tolerance phenomenon is a nitrate-
free interval. Intermittent administration of NTG patches
allowing a nitrate-free interval of 8 to 12 h has been shown
to retain nitrate sensitivity, with the disadvantage of a lack
of protection during this period. Another potential problem
of a nitrate-free interval may also be the development of
rebound ischemia. Treatment of experimental animals with
a nitrate-free interval was not able to normalize endothelial
dysfunction and hypersensitivity to vasoconstrictors (29).
During the nitrate-free interval, the frequency of angina
symptoms as well as of silent angina was significantly
increased (30). By treating patients intermittently with
NTG patches for a 5-day period, Azevedo et al. (31)
recently showed that this kind of regimen may prevent the
development of tolerance. Acute removal of the patch,
however, increased the coronary vasomotor responses to
ACh, suggesting that the rebound phenomena may be, at
least in part, secondary to the development of endothelial
dysfunction (31). These data clearly indicate that the phe-
nomenon of NTG-induced endothelial dysfunction cannot
be prevented by a nitrate-free interval.
If oxidative stress is important for tolerance and cross-
tolerance, antioxidants or drugs, which are able to reduce
oxidative stress within vascular tissue, should be able to
positively influence both phenomena. Recent small studies
in patients with CAD and heart failure indeed demon-
strated that the development of tolerance is beneficially
influenced by vitamin C (32,33), vitamin E (34) and
angiotensin-converting enzyme (ACE) inhibitors (35,36).
In addition, results from randomized trials in patients with
heart failure (37) and acute myocardial infarction (1) indi-
cate beneficial effects of nitrate therapy in combination with
ACE inhibitors. It is tempting to speculate that the bene-
ficial effects of ACE inhibitors are mediated at least in part
due to the prevention of tolerance and cross-tolerance
during NTG therapy.
WHAT QUESTIONS ARE
RAISED BY THE PRESENT STUDY
Although the oxidative stress concept is an attractive one to
explain the cross-tolerance phenomenon presented by Gori
et al. (9), the presented data only indicate that basal as well
as stimulated vascular NO bioavailability is disturbed in
response to long-term NTG treatment. In particular, the
question whether there is dysfunctional NOS III in vessels
from NTG-treated patients has not yet been answered. For
example, the authors discuss that L-NMMA can be used as
a tool to study NOS III uncoupling, although studies with
the NOS III enzyme indicated that L-NMMA, in contrast
to NG-nitro-L-arginine or its methylester, cannot inhibit
superoxide production (38).
The concept of NOS III uncoupling as a mechanism of
cross-tolerance requires further studies, which are able to
demonstrate that NTG-induced endothelial dysfunction is
improved by the modulation, e.g., of intracellular BH4 levels
with substances such as BH4 itself, BH4 precursors such as
sepiapterin or substances that increase intracellular BH4
levels like folic acid. In addition, studies have to be per-
formed to show whether L-arginine supplementation or
therapy with antioxidants such as vitamin C may prevent
the development of endothelial dysfunction during long-
term NTG treatment. It will also be interesting to see how
patients with CAD and pre-existing endothelial dysfunction
will respond to NTG therapy in this endothelial function
model and whether the inhibition of oxidative stress by
antioxidants is able to prevent tolerance as cross-tolerance.
Other clinically relevant questions are whether endothe-
lial dysfunction occurs in response to intermittent treatment
with mononitrates and dinitrates and whether it occurs with
other nitrovasodilators such as molsidomine. What is the
time course of endothelial dysfunction development and is
there a dose dependency? Why does endothelial dysfunction
develop in a vessel region such as the arterioles, where
nitrates have little or no vasodilator potency (39)? Answers
to all these questions would greatly enhance our under-
standing of mechanisms leading to tolerance and cross-
tolerance.
SUMMARY AND CLINICAL IMPLICATIONS
In summary, there is mounting evidence that systemic
therapy with NO via organic nitrates hits the endothelium
in patients with CAD (10,31) and even in healthy control
subjects (9). One mechanism contributing to this phenom-
enon may be a nitrate-induced stimulation of vascular
superoxide production. Overall, this may represent a kind of
biochemical baroreflex, in which the NTG-induced in-
creases in vascular NO are diminished due to local degra-
dation by superoxide. Treatment of patients with CAD with
ACE inhibitors and HMG-CoA reductase inhibitors have
been shown to improve endothelial dysfunction and simul-
taneously to improve prognosis. The present study indicates
that nitrates cause endothelial dysfunction and a recent
meta-analysis indicates that nitrates may worsen the prog-
nosis in patients with ischemic heart disease (3). However,
further studies are required to understand the precise nature
of the mechanisms underlying NTG-induced endothelial
dysfunction. These findings should be helpful to develop
strategies for preventing these NTG-induced side effects.
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